featured
2022 Top Story in Advanced Melanoma: Response-Driven Therapy After Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: